You are here

Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43DK101304-01
Agency Tracking Number: R43DK101304
Amount: $224,550.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDDK
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
32 RIVERSIDE DR, LINCOLN, RI, 02865-1511
DUNS: 78513201
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 RONALD WOLFF
 (401) 345-5979
 wolffpack12329@hotmail.com
Business Contact
 ANDREW MALLON
Phone: (401) 345-5979
Email: AndrewMallon@CalistaTherapeutics.co
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled nebulizer dosing and an efficacy that is predictive of clinical effect. CF is a common inherited disease that causes thick mucus in the lungs, digestive tract and other tissues. CF life expectancy is just 37.4 years and currently there is no approved treatment for the majority of CF patients. CF is a major unmet medical need. Calcaftor acts by inhibiting a CFTR trafficking protein CAL that promotes loss of CFTR from the epithelial membrane and premature lysosomal digestion. This Phase I SBIR will undertake critical proof of concept studies into the safety and pharmacokinetic distribution of Calcaftor following pulmonar

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government